Edwards Lifesciences (EW) PT Raised to $155 at Canaccord Genuity on 2Q Beat; 'Keep Buying... Upside to Raised Guidance in the Cards'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Edwards Lifesciences (EW) PT Raised to $130 at Stifel; Reiterates Buy
July 27, 2017 8:30 AM EDTStifel raised its price target on Edwards Lifesciences (NYSE: EW) to $130.00 (from $118.00) while maintaining a Buy rating. For 3Q17, the company anticipates revenue between $810M-$850M with EPS at $0.80-$0.90 (mid-point: $0.85).
For 2017, Edwards now expects full-year revenue at the higher end of the $3.2 billion... More
Edwards Lifesciences (EW) PT Raised to $132 at Jefferies
July 27, 2017 7:33 AM EDTJefferies raised its price target on Edwards Lifesciences (NYSE: EW) to $132.00 (from $115.00) while maintaining a Buy rating following the company's 2Q. EW put up another impressive TAVR Q with +23.3% underlying y/y growth and +7% growth sequentially. After adding back $22.5mn of German inventory... More
Edwards Lifesciences (EW): TAVR Outperformance Drives A PT Increase - Cowen
July 27, 2017 6:49 AM EDTCowen analyst, Joshua Jennings, reiterated his Outperform rating on shares of Edwards Lifesciences (NYSE: EW) and raised his price target to $135 after S3s strong sequential U.S. growth, international TAVR outperformance, outsized margin results and a ~$0.07 EPS beat (adjusting for the... More
Edwards Lifesciences (EW) Tops Q2 EPS by 20c; Raises Outlook
July 26, 2017 4:19 PM EDTEdwards Lifesciences (NYSE: EW) reported Q2 EPS of $1.08, $0.20 better than the analyst estimate of $0.88. Revenue for the quarter came in at $842 million versus the consensus estimate of $840.06 million.
GUIDANCE:
Edwards Lifesciences sees FY2017 EPS of $3.65-$3.85, versus the consensus of... More
